Table 5.

Summary of adverse events reported by least two subjects in each study

SRD study
			PF-04457845 dose
Adverse event	Placebo Cohort 1* (n = 9)	Cohort 2† (n = 12)	0.1 mg (n = 9)	0.3 mg (n = 9)	1 mg (n = 9)	3 mg (n = 9)	10 mg (n=9)	20 mg (n=9)	40 mg (n=9)
Number of subjects with adverse events	2	4	1	1	1	2	4	4	1
Number of subjects with treatment-related adverse events	0	1	0	0	0	1	2	1	0
Excoriation	1 (0)	0	1 (0)	0	1 (0)	0	2 (0)	0	0
Somnolence	0	1 (1)	0	0	0	1 (1)	1 (1)	0	0
Eye pain	0	0	0	0	0	0	0	1 (0)	1 (0)
Pyrexia	0	1 (0)	0	0	0	0	0	0	1 (0)
Arthralgia	0	1 (0)	0	0	0	0	1 (1)	0	0
Rhinorrhoea	0	1 (0)	0	0	0	0	1 (0)	0	0

MRD study
		PF-04457845 dose
Adverse event	Placebo (n = 8)	0.5 mg once daily (n = 8)	1 mg once daily (n = 8)	4 mg once daily (n = 8)	8 mg once daily (n = 8)
Number of subjects with adverse events	4	2	3	2	2
Number of subjects with treatment-related adverse events	4	2	3	2	1
Faeces hard	2 (2)	2 (2)	2 (2)	0	0
Headache	0	2 (2)	0	0	1 (1)
Oropharyngeal pain	1 (0)	1 (0)	0	0	0

Values are numbers of subjects with adverse events (treatment-related adverse events).

^*Subjects in cohort 1 received placebo, 0.1 mg, 1 mg and 10 mg PF-04457845.

^†Subjects in cohort 2 received placebo, 0.3 mg, 3 mg, 20 mg and 40 mg PF-04457845.